Brokerages Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Target Price at $158.69

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has earned a consensus recommendation of “Buy” from the seventeen brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $158.6875.

PVLA has been the subject of a number of research reports. Oppenheimer restated an “outperform” rating and set a $200.00 target price on shares of Palvella Therapeutics in a research note on Monday, December 15th. Chardan Capital raised their price objective on shares of Palvella Therapeutics from $110.00 to $174.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Canaccord Genuity Group boosted their price objective on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Cantor Fitzgerald increased their target price on Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th.

Palvella Therapeutics Stock Down 7.4%

PVLA opened at $85.30 on Monday. Palvella Therapeutics has a 12-month low of $12.10 and a 12-month high of $114.69. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -32.43 and a beta of -0.16. The business has a 50 day moving average of $97.37 and a 200-day moving average of $70.38.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). As a group, analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 12,906 shares of company stock worth $1,205,980 over the last three months. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Palvella Therapeutics

A number of institutional investors have recently bought and sold shares of PVLA. Aspiriant LLC bought a new position in shares of Palvella Therapeutics during the third quarter worth approximately $367,000. Frazier Life Sciences Management L.P. grew its position in Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after buying an additional 32,388 shares in the last quarter. Clio Asset Management LLC bought a new position in Palvella Therapeutics during the 2nd quarter worth $2,063,000. XTX Topco Ltd acquired a new position in Palvella Therapeutics in the 2nd quarter valued at $399,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Palvella Therapeutics during the 1st quarter valued at $533,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.